<DOC>
	<DOCNO>NCT00679380</DOCNO>
	<brief_summary>This multicentre , randomise , double-blind , double-dummy , parallel group comparative study patient mild moderate , active ulcerative colitis . The study compare budesonide-MMX™ 6 mg budesonide-MMX™ 9 mg tablet placebo Entocort® 3 x 3 mg capsule , four parallel group patient 8 week treatment period . After screen visit , patient enter washout period 2 day , randomise follow four treatment group : budesonide-MMX™ tablet ( 6 mg ) , budesonide-MMX™ tablet ( 9 mg ) , Entocort® capsule ( 3 x 3 mg ) placebo ( tablet capsule ) , administer day breakfast . Hence , patient receive , morning breakfast , either one budesonide-MMX™ 6 mg budesonide MMX™ 9 mg tablet 3 placebo Entocort® matching capsule , three Entocort® 3 mg capsule one placebo budesonide-MMX™ matching tablet , one placebo budesonide-MMX™ match tablet three placebo Entocort® matching capsule .</brief_summary>
	<brief_title>( CB-01-02/02 ) Randomized Placebo Controlled Trial Budesonide-multi-matrix System ( MMX™ ) 6 mg 9 mg Patients With Ulcerative Colitis</brief_title>
	<detailed_description>Each patient receive one follow regimen morning breakfast : 1 . One budesonide MMX® 6 mg tablet plus three placebo Entocort enteric-coated ( EC® ) overencapsulated capsule , 2 . One budesonide MMX® 9 mg tablet plus three placebo Entocort EC® overencapsulated capsule , 3 . Three placebo Entocort EC® overencapsulated capsule plus one placebo budesonide MMX® tablet , 4 . Three Entocort EC® 3 mg overencapsulated capsule plus one placebo budesonide MMX® tablet , daily eight week . Hence , patient take four tablets/capsules per day active placebo study medication per randomization schedule . Placebo tablet Budesonide MMX® placebo overencapsulated capsule Entocort EC® use maintain study blind use double-dummy technique . During study , five visit clinical center schedule : one Screening three double-blind treatment period ( Day 1 , Day 14 , Day 28 Day 56 ) . A safety follow-up visit take place 2 week final study visit . If patient withdrawn study Day 56 , ask attend study center soon possible thereafter Final visit assessment conduct .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients fulfil follow criterion screen visit eligible participation study : Male female patient , 1875 year old , suffer ulcerative colitis least 6 month . Diagnosis ulcerative colitis active phase , mild moderate entity Ulcerative Colitis Disease Activity Index ( UCDAI ) ≥ 4 ≤ 10 accord Sutherland . All female childbearing potential must negative serum pregnancy test immediately prior enrollment . In addition , female childbearing potential must agree completely abstinent use accepted form contraception throughout entire study period . Accepted form contraception define failure rate &lt; 1 % properly apply include : combination oral pill , intrauterine device , sterilise partner stable relationship . Female subject must also actively breastfeed entire study period . Ability comprehend full nature purpose study , include possible risk side effect . Ability cooperate investigator comply requirement entire study . Must able understand voluntarily sign write informed consent prior inclusion study . Patients meet follow criterion screen visit exclude study participation : Patients limited distal proctitis ( anal verge 15 cm pectineal line ) . Patients severe ulcerative colitis ( UCDAI &gt; 10 ) . Patients infectious colitis . Evidence history toxic megacolon . Severe anaemia , leucopaenia granulocytopaenia . Use oral rectal steroid last 4 week . Use immunosuppressive agent last 8 week study . Use anti tumour necrosis factor alpha ( antiTNFα ) agent last 3 month . Concomitant use rectal preparation . Concomitant use antibiotic . Concurrent use cytochrome P450 3A4 ( CYP3A4 ) inducer CYP3A4 inhibitor . Patients verify , presume expected pregnancy ongoing lactation . Patients liver cirrhosis , evident hepatic renal disease insufficiency , and/or severe impairment biohumoural parameter ( i.e . 2 x upper limit normal alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyl transpeptidase ( GGT ) creatinine ) . Patient severe disease organ system . Patients local systemic complication pathological state require therapy corticosteroid and/or immunosuppressive agent . Patients diagnose type 1 diabetes . Patients diagnose , family history , glaucoma . All patient know hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , accord local privacy policy . Participation experimental therapeutic study last 3 month . ( Note : patient participate observational study exclude ) . Any medical condition principal investigator 's opinion would make administration study drug study procedures hazardous subject obscure interpretation adverse event ( AEs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ulcerative colitis</keyword>
</DOC>